Do inactivating mutations or inhibition of ANGPTL4 reduce triglyceride levels and the risk of coronary artery disease?
Human carriers of E40K and other inactivating mutations in ANGPTL4, as well as mice and monkey models
Inactivating mutations in ANGPTL4 (E40K and others) or pharmacological inhibition of Angptl4
Noncarriers or control animals
Triglyceride levels and risk of coronary artery diseasehard clinical
Inactivating mutations or inhibition of ANGPTL4 are associated with lower triglycerides and reduced risk of coronary artery disease, suggesting it as a potential therapeutic target for cardiovascular prevention.
Carriers of E40K and other inactivating mutations in ANGPTL4 had lower levels of triglycerides and a lower risk of coronary artery disease than did noncarriers. The inhibition of Angptl4 in mice and monkeys also resulted in corresponding reductions in these values. (Funded by Regeneron Pharmaceuticals.).
Building similarity graph...
Analyzing shared references across papers
Loading...
Frederick E. Dewey
Viktoria Gusarova
Colm O’Dushlaine
New England Journal of Medicine
Regeneron (United States)
Geisinger Health System
Building similarity graph...
Analyzing shared references across papers
Loading...
Dewey et al. (Wed,) studied this question.
www.synapsesocial.com/papers/69e8ce4799fb462f768581f4 — DOI: https://doi.org/10.1056/nejmoa1510926
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: